|Validation of an Automated Cell-Based Bioluminescent TNFa Blocker Bioassay|
Brad Larson, Tracy Worzella, Rich Moravec, Neal Cosby, Frank Fan, Teresa Surowy and Peter Banks
TNFa blocker biopharmaceuticals represent an important and successful class of protein drugs used in the treatment of several autoimmune diseases. Bioassays are indispensible tools in biopharmaceutical drug development and commercialization that are used to quantify biological activity and stability of drugs or drug candidates. The automation of these assays can serve to create an accurate, robust process which can allow the researcher to perform other more important functions.
|Automation of a Generic Fluorescence Methyltransferase Activity Assay|
X. Amouretti, P. Brescia, P. Banks, G. Prescott, Meera Kumar
Epigenetic processes are attracting considerable attention in drug discovery as their fundamental roles in controlling normal cell development and contributions to disease states become more clearly defined. This work combines a fluorescence-based assay with liquid handling and dispensing instrumentation and a multi-mode reader which can be used to monitor the biological activity of the histone methyltransferase (HMT) G9a, a model system.
|Automation of a Novel Cell-Based ELISA for Cell Signaling Pathway Analysis|
Wendy Goodrich, Peter Banks, Ron Osmond, Antony Sheehan
Monitoring and quantifying cell signaling pathways is critical for understanding the behavior of cell processes and many disease states. Monitoring and quantifying cell signaling pathways is critical for understanding the behavior of cell processes and many disease states.
|Improving Cell-Mediated Cytotoxicity Assessment through the Use of an Automated Luminescent ADCC Assay|
Brad Larson, Sumant Dhawan, Shalini Wadwani, and Peter Banks
Assays that can assess the ability of a biosimilar to act in a manner similar to the original biologic have seen increased interest. This poster describes the use of a non-radioactive luminescent chemistry to simplify the assay process and provide improved data quality.
|Antigen Determination in Autoimmune Hepatitis Type1|
Naveen L Gupta, S Nayak, S Shakeyavar
Objectives of this project were to exploit the database in indian setting to determine nuclear antigens as target for antinuclear antibodies (ANA) in patients of autoimmune hapatitis (AIH) type1.
|High Content Analysis of Neural Stem Cell Expansion and Differentiation|
Oksana Sirenko, Allan C. Powe, Steven L. Stice, Karen Cook, Nick Callamaras, Jayne Hesley, Xin Jiang and Evan F. Cromwell
Automated assay methods for monitoring neural stem cell expansion and differentiation using stem cell derived neural cell lines and high content imaging systems have been described.
|Global Gene Expression Changes Induced In Primary Human Hepatocytes By Thiazolidinediones Upon Repeat Dosing of HepatoPac™ Cultures|
Michael McVay and Salman R. Khetani
An assessment of global gene expression changes in HepatoPac, a micropatterned co-culture of hepatocytes and stromal cells.
|High-Throughput Campaign to Identify Reversible Small Molecule Inhibitors of p97|
Kelin Li, Tsui-Fen Chou, Kevin Frankowski, Brian E. Nordinc, Patrick Porubsky, Mathew P. Patricellic, Han-Jie Zhou, Sam Gerritz, Raymond J. Deshaies, Jeffrey Aubé, Frank J. Schoenen*
The AAA ATPase p97 is a critical factor in maintaining protein homeostasis in eukaryotic cells. Two probe compounds ML240 and ML241 were developed that both inhibit p97 ATPase activity with an IC50 of approximately 100 nM, and block degradation of p97-dependent proteasome substrate with an IC50 of approximately 900 nM and 3500 nM, respectively. They specifically targeted p97, exhibited markedly different potencies for activating executioner caspases and blocking cell growth.
|Using the Promega GloSensor™ cAMP technology on the FLIPR® Tetra system for live cell Gi- and Gs- coupled GPCR second messenger assays|
J. Pschorr, S. Lydford, C. Crittenden and Y.-W. Chen
Detection of Gs- and Gi-coupled GPCR second messenger signal activity has been traditionally accomplished using endpoint assays such as radioactive binding or cAMP assays that require cell lysis. This poster demonstrates the use of the modified luminescent firefly luciferase-based Promega GloSensor™ cAMP Assay on the FLIPR® Tetra system to enable detection of cAMP mediated Gs- and Gi-coupled GPCR activity in a true kinetic assay.